A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer

Table 2

Characteristics of pancreatic cancer patients.

Characteristics	No. (%)			value
	Entire cohort ()	Training group ()	Validation group ()
Age (years)				0.4868
≤60	58 (32.58%)	26 (29.55%)	32 (35.56%)
>60	120 (67.42%)	62 (70.45%)	58 (64.44%)
Gender				0.2222
Female	80 (44.94%)	35 (39.77%)	45 (50%)
Male	98 (55.06%)	53 (60.23%)	45 (50%)
Histologic grade				0.3903
G1	31 (17.42%)	14 (15.91%)	17 (18.89%)
G2	95 (53.37%)	51 (57.95%)	44 (48.89%)
G3	48 (26.97%)	20 (22.73%)	28 (31.11%)
G4	2 (1.12%)	1 (1.14%)	1 (1.11%)
Unknown	2 (1.12%)	2 (2.27%)	0 (0%)
Pathologic stage				0.2498
Stage I	21 (11.8%)	15 (17.05%)	6 (6.67%)
Stage II	146 (82.02%)	68 (77.27%)	78 (86.67%)
Stage III	3 (1.69%)	1 (1.14%)	2 (2.22%)
Stage IV	5 (2.81%)	2 (2.27%)	3 (3.33%)
Unknown	3 (1.69%)	2 (2.27%)	1 (1.11%)
T stage				0.6067
T1	7 (3.93%)	5 (5.68%)	2 (2.22%)
T2	24 (13.48%)	14 (15.91%)	10 (11.11%)
T3	142 (79.78%)	67 (76.14%)	75 (83.33%)
T4	3 (1.69%)	1 (1.14%)	2 (2.22%)
Unknown	2 (1.12%)	1 (1.14%)	1 (1.11%)
M stage				0.3219
M0	79 (44.38%)	44 (50%)	35 (38.89%)
M1	5 (2.81%)	2 (2.27%)	3 (3.33%)
Unknown	94 (52.81%)	42 (47.73%)	52 (57.78%)
N stage				0.8822
N0	50 (28.09%)	25 (28.41%)	25 (27.78%)
N1	123 (69.1%)	60 (68.18%)	63 (70%)
Unknown	5 (2.81%)	3 (3.41%)	2 (2.22%)